Trading Report: Today: Sinovac Biotech Ltd. (SVA) Issues Quarterly Earnings Results

Today: Sinovac Biotech Ltd. (SVA) Issues Quarterly  Earnings Results

Sinovac Biotech Ltd. (NASDAQ:SVA) issued its earnings results on Monday. The biopharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.05 by $0.01. The firm had revenue of $28.74 million for the quarter, compared to the consensus estimate of $16.76 million. Sinovac Biotech had a negative net margin of 17.94% and a negative return on equity of 10.26%.

Sinovac Biotech (NASDAQ:SVA) opened at 6.19 on Monday. The company’s market cap is $352.43 million. The company’s 50-day moving average is $6.07 and its 200-day moving average is $5.95. Sinovac Biotech has a 12 month low of $4.38 and a 12 month high of $7.16.

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. State Street Corp bought a new position in Sinovac Biotech during the second quarter valued at approximately $100,000. TFS Capital LLC increased its position in Sinovac Biotech by 86.8% in the second quarter. TFS Capital LLC now owns 24,650 shares of the biopharmaceutical company’s stock worth $146,000 after buying an additional 11,451 shares during the period. OMERS ADMINISTRATION Corp increased its position in Sinovac Biotech by 5.6% in the second quarter. OMERS ADMINISTRATION Corp now owns 35,700 shares of the biopharmaceutical company’s stock worth $212,000 after buying an additional 1,900 shares during the period. Panagora Asset Management Inc. increased its position in Sinovac Biotech by 4.7% in the second quarter. Panagora Asset Management Inc. now owns 42,816 shares of the biopharmaceutical company’s stock worth $254,000 after buying an additional 1,929 shares during the period. Finally, Credit Suisse AG increased its position in Sinovac Biotech by 48.2% in the third quarter. Credit Suisse AG now owns 89,428 shares of the biopharmaceutical company’s stock worth $527,000 after buying an additional 29,085 shares during the period. 19.92% of the stock is currently owned by institutional investors.

Separately, TheStreet downgraded shares of Sinovac Biotech from a “hold” rating to a “sell” rating in a research report on Wednesday, August 24th.

Sinovac Biotech Company Profile

Related posts

Leave a Comment